This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
The European Commission has cleared the acquisition of Hospira by Pfizer in phase 1. The clearance is subject to the divestment of some sterile injectable drugs and one biosimilar pipeline.
A CRA team advised and provided economic support to Pfizer during the pre-notification and phase 1 proceedings in front of the European Commission.
For more details, please see the Commission’s press release.
In this new episode of Concurrences’ Antitrust Code Podcast, CRA’s Oliver Latham interviews Pierre Régibeau. He reviews the key developments that took place...
Big Tech continues to be on an acquisition spree. On 28 March of this year, the European Commission unconditionally approved Google’s acquisition of Photomath,...
Matteo Foschi is a speaker during the conference. For more information on this event, click here.
The Annual CRA Brussels Conference returns to the Steigenberger Wiltcher’s Hotel on Wednesday 6 December 2023. This year’s conference will address the state...
